An Echelon Media Company
Monday November 9th, 2026

Does Covid vaccines deprive visa and reduce fertility? – fact-checked

ECONOMYNEXT – Sajith* has vowed to wait until any vaccine other than China-made Sinopharm vaccine is made available.

The 28-year old youth from a Colombo suburb area is waiting to leave Sri Lanka once all the Covid-19 restrictions are over.

“Sinopharm could deny me a visa from the UK. I am also concerned over possible fertility issues with regard to vaccines,” he told EconomyNext, asking not to reveal his real identity given he has yet to be vaccinated.

“Many of my friends have decided not to get the vaccines, because there are some stories that these vaccines reduce fertility. But I want to get the vaccines because they are important for me to go abroad. Otherwise I too prefer to join my friends”

Sajith is one of those thousands of Sri Lankan youth who have been taking a risk without any vaccines so far despite top health officials have advised Sri Lankans to get any vaccine available at the moment.

However, there has been claims of visa denial and fertility reduction have hindered the latest vaccination programme among the people aged 20-29 years.

Sri Lanka started vaccinating this group from September 06 with the above 30 years of age groups being almost completely vaccinated by the government’s vaccination drive.

As of October 29, health authorities have said they had vaccinated nearly 60 percent out of a total 3.3 million in the 20-29 age group with the first dose and nearly 19 percent with both doses.

The vaccination is done mainly using the Chinese manufactured Sinopharm vaccine, the most used vaccine in the country along with AstraZeneca, Moderna, Pfizer, and Sputnik V.

False and misleading claims about Covid-19 vaccines, fertility and visa denial are still circulating online, despite not being supported by evidence.

The claims on some countries requesting travelers, students and employees coming from abroad to be vaccinated with a specific vaccine which has been recognized by the country has weighed on Sri Lanka’s vaccination programme.

People say they have got social media messages saying that travelers who had not been immunized with a particular recognized vaccine are being sent for mandatory quarantine or denied entry to the country.

“Along with other information circulating in the social media, the information saying countries won’t accept Sinopharm as a valid vaccine for the travelers to enter the country is a major issue” a student of the Sri Jayewardenepura University told EconomyNext.

“Most of the students in the university expects to travel abroad for higher education after the completion of the course in university”

“With that more students are demanding Pfizer of Moderna vaccines”

Fact checking on visa entry for those fully vaccinated with Sinopharm

According to a foreign ministry document on the entry requirement by various countries seen by EconomyNext, much of the information about not being able to get a visa after taking a certain Covid 19 vaccine is wrong.

An official who is dealing with inquiries over vaccine requirements for visas said people do not accept what they say.

“When we say you can take Sinopharm, these people who are not informed say they can’t take it because their desired country doesn’t accept it,” the official told EconomyNext on condition of anonymity because he is not allowed to officially talk to the media.

The foreign ministry document shows some countries do not require vaccines and other countries requesting mandatory vaccination do not reject Sinopharm.

However, Sri Lanka is currently included in the list of high risk countries by Bulgaria, Bahrain, Qatar, Denmark, Finland, Germany, Malta, Turkey, Slovakia, and Thailand due to delta covid-19 variant.

The officials said when Sri Lanka is in the list of high risk countries, even if the people have been vaccinated with Prizer or Moderna, still they will not be allowed to enter the desired country because of Sri Lanka being in the red list.

“But in countries like Australia if you have been vaccinated with a vaccine that has not been approved by their authorities, you will need to undergo a quarantine time period, can be 10,14 or 21 days and should be tested negative in a PCR test before being released,” the official said.

“That is the requirement of those countries if you have taken a different vaccine.”

“if you are a person with some medical condition that has been advised to take a specific vaccination. In those cases, they have to make a special request to the Director General of Health, and he will give the approval after going case by case to get that specific vaccine.”

He said for ordinary travelers, there is no issue with regard to vaccines.

“Many countries now recognize the vaccines and if you have been jabbed with a vaccine that has not been recognized there, then you will have to undergo the quarantine period. But there are no restrictions saying you can’t enter a country.”

He said some Sri Lankans are demanding specific vaccines to save the money they have to pay in the quarantine process.

“Even when you go to China after being jabbed with the Sinopharm vaccine, you will have to go under a quarantine period for 21 days.”

Saudi Arabia requests the travelers to take a booster dose in the event of people having only got two Sinopharm.

“But they (Saudi) have allowed them to take a booster dose before coming or they have given the facility to take the booster dose after coming to Saudi Arabia,” he said.

“But our people want to take it before going there, thinking they won’t be accepted or there will be issues.

“In Europe, Germany and France were the only countries that did not accept the Sinopharm vaccine. But we are checking to see whether they have changed the rules. Because from time to time they change the rules.”

“But other European countries, like the UK, Italy and others, do not have such restrictions.”

Fact checking on Covid vaccines reducing fertility 

Health authorities said currently there is no evidence to prove any theory circulating in these platforms.

The Centre for Diseases Control and Prevention (CDC) in the USA has said there is currently no evidence that antibodies made following COVID-19 vaccine or its ingredients would cause any problems with becoming pregnant now or in the future.

CDC said, many people have become pregnant after receiving a COVID-19 vaccine, including some who got vaccinated during COVID-19 vaccine clinical trials.

In addition, a recent report using the data showed that 4,800 people had a positive pregnancy test after receiving a first dose of an mRNA COVID-19 vaccine.

 Another report using data from 8 U.S. healthcare systems documented more than 1,000 people who completed COVID-19 vaccination (with any COVID-19 vaccine) before becoming pregnant.

CDC has further said currently no evidence shows that any vaccines, including COVID-19 vaccines, cause male fertility problems.

Another study shows that the vaccines would not remain in ovaries as spreaded by social media.

The study involved giving rats a much higher dose of vaccine than that given to humans (1,333 times higher).

Only 0.1% of the total dose ended up in the animals’ ovaries, 48 hours after injection.

Far more – 53% after one hour and 25% after 48 hours – was found at the injection site (in humans, usually the arm). The next most common place was the liver (16% after 48 hours), which helps get rid of waste products from the blood.

Source: https://healthfeedback.org/claimreview/covid-19-vaccines-dont-affect-ovaries-or-fertility-in-general-the-vaccines-are-highly-effective-at-preventing-illness-and-death/

The vaccine is delivered using a bubble of fat containing the virus’s genetic material, which kick-starts the body’s immune system.

And those promoting this claim cherry-picked a figure which actually referred to the concentration of fat found in the ovaries.

Fat levels in the ovaries did increase in the 48 hours after the jab, as the vaccine contents moved from the injection site around the body.

But, crucially, there was no evidence it still contained the virus’s genetic material.

We don’t know what happened after 48 hours as that was the limit of the study.

A recent small study of 45 healthy men who received an mRNA COVID-19 vaccine looked at sperm characteristics, like quantity and movement, before and after vaccination.

Researchers found no significant changes in these sperm characteristics after vaccination.

Fever from illness has been associated with short-term decrease in sperm production in healthy men, it said.

“Although fever can be a side effect of COVID-19 vaccination, there is no current evidence that fever after COVID-vaccination affects sperm production,” the CDC said.

Also another recent study done in South Florida, USA has shown that while COVID-19 may harm the lungs, it’s a systemic disease that can also affect the heart, kidneys, brain and other organs, and those effects can last long after someone has recovered.

Among the list of ailments, mounting evidence suggests that COVID-19 may sabotage men’s sexual health.

The research was done by collecting the penile tissue from patients undergoing surgery for penile prosthesis surgery due to severe Erectile Dysfunction under an Institutional Review Board of the University of Miami Miller School of Medicine approved protocol.

Patients’ ages ranged from 65 to 71 years old, and all were of Hispanic ethnicity.

Two specimens were obtained from males with a history of COVID-19 infection and two specimens were obtained from men with no history of infection.

The results of the research have revealed that widespread endothelial cell dysfunction from COVID-19 infection can contribute to resultant erectile dysfunction. Future studies will evaluate novel molecular mechanisms of how COVID-19 infection can lead to Erectile Dysfunction.

This shows vaccination does not affect fertility, but the effect of Covid-19 infection does.

Sri Lanka rupee closes at 332.53/59 to US dollar spot, bond yields edge up

ECONOMYNEXT – Sri Lanka’s rupee closed at 332.53/59 to the US dollar spot on Monday, from 332.55/60 the previous day, while bond yields closed higher, dealers said.

A bond maturing on 15.09.2029 closed at 190/98 percent, up from 10.85/95 percent.

A bond maturing on 01.08.2030 closed at 11.07/12 percent, up from 11.05/10 percent.

A bond maturing on 01.02.2031 closed at 11.30/40 percent, up from 11.10/15 percent.

A bond maturing on 15.12.2032 closed at 11.65/70 percent, up from 11.55/65 percent.

A bond maturing on 01.11.2033 closed at 11.95/12.00 percent, up from 11.90/95 percent.

A bond maturing on 15.10.2034 closed at 12.10/15 percent, up from 12.05/12 percent.

A bond maturing on 15.08.2036 closed at 12.40/50 percent, up from 12.30/40 percent. (Colombo/Nov9/2026)

Continue Reading

Sri Lanka stocks close up 1.37-pct, banks lead turnover

ECONOMYNEXT – Sri Lanka’s Colombo Stock Exchange closed up on Monday, CSE data showed, with the benchmark All Share Price Index moving up 1.37 percent.

The ASPI was up 291.72 points at 21,531.37, while the more liquid S&P SL20 was up 1.67 percent, or 100.96 points, at 6,146.34.

Positive contributors to the ASPI were Commercial Bank of Ceylon (up 2.86 percent at 216.00 rupees), Hatton National Bank (up 1.52 percent at 399.75 rupees), Asiri Hospital Holdings (up 12.86 percent at 31.60 rupees), Tokyo Cement Company (up 5.22 percent at 84.70 rupees), and Access Engineering (up 3.93 percent at 81.90 rupees).

Carson Cumberbatch (down 4.24 percent at 712.00 rupees), Richard Pieris and Company (down 2.43 percent at 28.10 rupees), LOLC Holdings (down 0.62 percent at 400.00 rupees), Renuka Holdings (down 2.63 percent at 37.00 rupees), and Chevron Lubricants Lanka (down 0.61 percent at 204.25 rupees) were top negative contributors.

Market turnover was 3.33 billion rupees. The S&P/CSE Banks Industry Group led turnover with 667.76 million rupees.

The session saw heavy crossings, according to Raynal Wickremeratne, Head of Research and Strategy at NDB Securities. Significant crossings included Keells (23 million rupees), Distilleries Company (27.7 million rupees), Sunshine Holdings (30.6 million rupees), Commercial Bank (32.4 million rupees), Ceylon Tobacco Company (35.6 million rupees), Hatton National Bank (39.5 million rupees), Prime Lands (40.5 million rupees), and HAS Holdings (41.5 million rupees).

In corporate news, Hayleys Retail Holdings Ltd announced it has partnered with supply chain software provider Blue Yonder to build and scale an AI-native grocery supermarket chain across Sri Lanka. (Colombo/Nov09/2026)

 

Continue Reading

Sri Lanka’s Hayleys Retail to launch supermarket chain with Blue Yonder

ECONOMYNEXT — Hayleys Retail Holdings Ltd has selected supply chain software provider Blue Yonder to build its grocery retail operations from the ground up, the two companies said in a joint statement.

Hayleys Retail, a member of Sri Lanka’s diversified conglomerate Hayleys Group, plans to open several stores in the near future to serve consumers across the country. The agreement marks Blue Yonder’s first retail customer in Sri Lanka.

“Our entry into supermarket retail is about bringing that same commitment to quality and reliability closer to everyday Sri Lankan consumers,” Mohan Pandithage, Chairman and Chief Executive of Hayleys PLC said.

“With Blue Yonder, our teams will have AI-driven insight to deliver a seamless, consistent shopping experience across every store,” he said.

Hayleys, which accounts for approximately 5 percent of Sri Lanka’s export income and operates across 17 business sectors, is entering the large-scale supermarket space by drawing on its group strengths in manufacturing, logistics, and services.

The company selected Blue Yonder to connect its data across merchandising and shelf space, deploy artificial intelligence agents to catch operational issues early, and scale its business into a national network without changing platforms.

The rollout will begin with merchandise operations to manage suppliers, items, costs, and pricing, followed by machine learning capabilities to forecast demand and balance store inventory during seasonal peaks.

“Hayleys Retail is choosing one where AI is the foundation rather than an add-on—connected data and agentic AI built into core merchandising operations, and planning that learns as the business grows,” Antonio Boccalandro, President, APAC at Blue Yonder said.

The retailer plans to use the platform to automate routine store tasks and adjust inventory according to real-time sales and local market trends as its store footprint grows. (Colombo/Nov09/2026)

 

Continue Reading

Sri Lanka’s Citrus Leisure extends Lotus Tower management pact

ECONOMYNEXT – Sri Lanka listed hospitality firm Citrus Leisure said it has extended an agreement to manage consumer-facing and entertainment spaces at the Colombo Lotus Tower, which includes revolving restaurant Blue Orbit, until June next year.

The initial agreement signed between Citrus Leisure and Colombo Lotus Tower Management Company (Private) Limited (CLTMC) is due to expire on December 11.

“The Board of Directors of CLTMC at meeting held on 2nd November 2026 has resolved to extend the term of the Management Agreement and continue the existing Management Agreement until 30th June 2027, to which the company has given its concurrence,” the company said in a market filing.

Citrus Leisure Plc opened its revolving restaurant at the Lotus Tower in December 2023.

The company signed a 3-year agreement with CLTMC in May 2023 to provide services in the management of (l) the banquet hall 1 on the 25th floor, (2) the banquet hall 2 on the 26th floor, (3) the revolving restaurant on the 27th floor, (4) the 6 suites situated on the 28th floor and the kitchen in the basement floor of the Colombo Lotus Tower.

The 350-meter or 1,150-feet tower, the tallest in South Asia, was built at a cost 104.3 million US dollars with 80 percent of the money borrowed from Exim Bank of China.

Located in the commercial heart of Colombo, the tower has been called a symbolic landmark of Sri Lanka as well as a colossal white elephant and has been mired in controversy for years. (Colombo/Nov9/2026)

Continue Reading

CIC Holdings Sept quarter net profit rises 20-pct to Rs1.7bn

ECONOMYNEXT — Sri Lanka conglomerate CIC Holdings recorded a net profit of 1.66 billion rupees for the quarter ended September 30, rising 20.3 percent from 1.38 billion rupees in the same quarter last year, interim accounts showed.

The group posted basic earnings per share of 0.87 rupees for the September quarter, up from 0.73 rupees a year earlier.

Quarterly revenue grew 3.4 percent to 20.89 billion rupees from 20.20 billion rupees, supported by broad-based growth across industrial solutions, livestock, and healthcare segments, which counterbalanced relative demand moderation in agricultural inputs.

Cost of sales rose 5.3 percent to 15.20 billion rupees, outpacing revenue growth and causing gross profit to contract marginally by 1.2 percent to 5.68 billion rupees.

Results from operating activities dropped 7.3 percent to 2.66 billion rupees from 2.87 billion rupees, impacted by higher operating overheads.

Selling expenses expanded 6.8 percent to 2.15 billion rupees, and general and administrative expenses climbed 5.8 percent to 1.07 billion rupees, while other operating income dropped 29.6 percent to 117.40 million rupees.

However, operating profits were cushioned by an impairment reversal on trade receivables of 85.83 million rupees, turning around from an impairment provision of 23.38 million rupees in the corresponding quarter last year.

Net finance costs climbed 35.4 percent to 712.25 million rupees from 526.01 million rupees.

The increase was driven by a 30.8 percent rise in finance expenses to 771.46 million rupees, primarily reflecting higher interest expenses on loans to finance elevated working capital and inventory requirements.

The quarter’s bottom line was strongly bolstered by CIC’s equity-accounted investment in John Keells Holdings PLC (JKH).

Share of profit from equity-accounted investees surged more than fourfold to 590.50 million rupees from 257.87 million rupees, driven by JKH’s strong profit expansion during the period.

The group also recognized a gain on bargain purchase of 55.59 million rupees during the quarter resulting from additional share purchases in JKH where the proportionate net asset value exceeded acquisition cost, compared to no such gain a year earlier.

With associate income gains offsetting operating margin contraction and higher borrowing costs, group pre-tax profit held virtually flat at 2.59 billion rupees, down 0.11 percent.

Income tax expense fell 29.4 percent to 606.24 million rupees from 858.71 million rupees, driving total group profit for the period up 14.1 percent to 1.98 billion rupees.

Total group assets stood at 108.58 billion rupees as of September 30, up from 99.75 billion rupees at the end of March 2026.

Group net asset value per share increased to 25.52 rupees from 22.10 rupees a year earlier.

CIC Holdings’ ordinary voting shares closed at 27.80 rupees at the end of September.(Colombo/Nov09/2026)

 

Continue Reading

Sri Lanka stocks trend up; ASPI gains 0.78-pct

ECONOMYNEXT – Sri Lanka’s Colombo Stock Exchange was trading higher on Monday, CSE data showed, with the benchmark All Share Price Index moving up 0.78 percent.

The ASPI was up 165.73 points at 21,405.38, while the more liquid S&P SL20 was up 0.61 percent, or 37.04 points, at 6,082.42.

Positive contributors to the ASPI were Commercial Bank (up 1.55 percent at 213.25 rupees), Ceylon Cold Stores (up 2.61 percent at 128.00 rupees), Asiri Hospital Holdings (up 10.00 percent at 30.80 rupees), Hemas Holdings (up 1.27 percent at 32.00 rupees), and Ambeon Holdings (up 6.02 percent at 37.00 rupees).

Namunukula Plantations (down 3.92 percent at 63.70 rupees), LOLC Holdings (down 0.62 percent at 400.00 rupees), and Chevron Lubricants Lanka (down 0.12 percent at 205.25 rupees) were top negative contributors.

Market turnover was 428.31 million rupees. Capital goods led turnover with 82.53 million rupees. (Colombo/Nov09/2026)

Continue Reading